# CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

> **NCT00092508** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 1725 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** OPC-6535
- **DRUG:** Asacol®

## Key facts

- **NCT ID:** NCT00092508
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 1725 (ESTIMATED)
- **Last updated:** 2007-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00092508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00092508, "CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00092508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*